RT @CalaisJeremie: In patients with advanced mCRPC with high volume of bone marrow disease, response to #PLUVICTO can help to keep a good b…
RT @CalaisJeremie: In patients with advanced mCRPC with high volume of bone marrow disease, response to #PLUVICTO can help to keep a good b…
RT @CalaisJeremie: In patients with advanced mCRPC with high volume of bone marrow disease, response to #PLUVICTO can help to keep a good b…
RT @CalaisJeremie: In patients with advanced mCRPC with high volume of bone marrow disease, response to #PLUVICTO can help to keep a good b…
RT @CalaisJeremie: In patients with advanced mCRPC with high volume of bone marrow disease, response to #PLUVICTO can help to keep a good b…
RT @CalaisJeremie: In patients with advanced mCRPC with high volume of bone marrow disease, response to #PLUVICTO can help to keep a good b…
RT @CalaisJeremie: In patients with advanced mCRPC with high volume of bone marrow disease, response to #PLUVICTO can help to keep a good b…
In patients with advanced mCRPC with high volume of bone marrow disease, response to #PLUVICTO can help to keep a good bone marrow function. Nice work from @UniFreiburg Team @felixfind #theranostics #PSMA #nuclearmedicine #prostatecancer https://t.co/WsuD
New article: Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression? https://t.co/aNVF3KjF6X #prostatecancer #oncology https://t.co/btm3Uaqmob